# Clinical Study to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease

> **NCT07166757** · PHASE1,PHASE2 · RECRUITING · sponsor: **XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.** · enrollment: 90 (estimated)

## Conditions studied

- Parkinson Disease (PD)

## Interventions

- **DRUG:** human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection

## Key facts

- **NCT ID:** NCT07166757
- **Lead sponsor:** XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-22
- **Primary completion:** 2028-03-30
- **Final completion:** 2029-03-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07166757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07166757, "Clinical Study to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07166757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*